---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002920"
form_type: "8-K"
ticker: null
cik: "0001183765"
company_name: "Molecular Templates, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:41:23.026485+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Molecular Templates Q1 net income $0.6M on revenue $11.1M; MT-6402 shows 2 PRs in HNSCC

## Summary
- Net income $0.6M ($0.11 basic EPS) vs $10.8M ($2.89) in Q1 2023; revenue $11.1M vs $36.6M.
- Cash and equivalents $6.8M; subsequent $9.5M financing closing supports ops into Q4 2024.
- MT-6402 monotherapy in HNSCC: 2 confirmed PRs (ongoing 10 & 20 months), 4 SDs in 7 evaluable.
- MT-8421 Phase 1 dose escalation ongoing; unique Treg depletion pharmacodynamics.

## SEC filing metadata
- accession: 0001171843-24-002920
- form_type: 8-K
- cik: 0001183765
- company_name: Molecular Templates, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1183765/000117184324002920/0001171843-24-002920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1183765/000117184324002920/f8k_051524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002920
- JSON: https://secwatch.observer/filing/0001171843-24-002920.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002920.txt

## Key facts
- Earnings Releases
  Molecular Templates, Inc. reported the first quarter of 2024 ended March 31, 2024 results: revenue $11.1 million, net income $0.6 million, EPS $0.11 per basic share and $0.08 per diluted share.
  - Period: the first quarter of 2024 ended March 31, 2024
  - Revenue: $11.1 million
  - Net income: $0.6 million
  - EPS: $0.11 per basic share and $0.08 per diluted share
  - Result: reported results
  source text: a net income attributable to common shareholders of $10.8 million, or $2.89 per basic and diluted share, for the same period in 2023. Revenues for the first quarter of 2024 were $11.1 million, compared to $36.6 million for the same period in 2023. Total research and development expenses for the first quarter of 2024 were $7.4 million, compared with $19.0 million for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1183765/000117184324002920/0001171843-24-002920-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.